| abstract |
The compounds of formula (1) are suitable for producing pharmaceutical products for prophylaxis and therapy in conditions in which an intensified activity of matrix metalloproteinase 13 is involved. These include conditions such as a degenerative joint condition, for example osteoporosis, spondylosis, condrolysis after trauma to the joints or prolonged immobilization of the joints after meniscus or kneecap injuries or ligament tears or a connective tissue condition such as collagen, periodontal conditions, wound healing disorders or a chronic condition of the musculoskeletal system such as acute and chronic arthritis, inflammatory, immunological or related to metabolism, arthropathies, myalgias and alterations of bone metabolism or ulceration, atherosclerosis or stenosis or an inflammatory condition or a cancer, tumor metastasis, cachexia, anorexia or septic shock. Compounds and processes for preparing them are also claimed. Claim 1: Use of the compound of formula (1) and / or all stereoisomeric forms of the compound of the formula (1) and / or mixtures of these forms in any ratio and / or a physiologically tolerable salt of the compound of the formula (1 ) to produce a pharmaceutical product for the prophylaxis and therapy of conditions in whose development an intensified activity of matrix metalloproteinase 13 is involved, in which A is a C or N atom, where A is unsubstituted or substituted with alkyl C1-4, n is the integer 1 or 2, R1 is 1) -C1-10 alkyl, where alkyl is linear or branched, 2) -C2-10 alkenyl, where alkenyl is linear or branched, 3) - C2-10 alkynyl, wherein alkynyl is linear or branched, 4) -C 1-4 alkyl -phenyl, 5) -C 1-4 alkyl-C3-6cycloalkyl, 6) -C3-6 cycloalkyl, or 7) -CH2CF3, and R2 is an atom of H or -C 1-4 alkyl. |